HR-positive, HER2-negative advanced breast cancer
Clinical trials for HR-positive, HER2-negative advanced breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR-positive, HER2-negative advanced breast cancer trials appear
Sign up with your email to follow new studies for HR-positive, HER2-negative advanced breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple drug combo aims to slow HR+/HER2- advanced breast cancer
Disease control OngoingResearchers are testing whether adding apatinib, a drug that blocks blood vessel growth, to a CDK4/6 inhibitor and hormone therapy helps control HR+/HER2- advanced breast cancer. The trial enrolls women aged 18 to 75 with confirmed HR-positive, HER2-negative invasive breast cance…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail aims to control advanced breast cancer
Disease control OngoingThis Phase 3 trial is testing a new drug called gedatolisib combined with fulvestrant, with or without palbociclib, in about 700 people with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The goal is to see if this combination can slow cancer growth bet…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase 3 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC